MX2023009445A - Compuestos de heterociclos tetraciclicos utiles como inhibidores de la integrasa del vih. - Google Patents

Compuestos de heterociclos tetraciclicos utiles como inhibidores de la integrasa del vih.

Info

Publication number
MX2023009445A
MX2023009445A MX2023009445A MX2023009445A MX2023009445A MX 2023009445 A MX2023009445 A MX 2023009445A MX 2023009445 A MX2023009445 A MX 2023009445A MX 2023009445 A MX2023009445 A MX 2023009445A MX 2023009445 A MX2023009445 A MX 2023009445A
Authority
MX
Mexico
Prior art keywords
tetracyclic heterocycle
heterocycle compounds
compounds useful
hiv integrase
integrase inhibitors
Prior art date
Application number
MX2023009445A
Other languages
English (en)
Spanish (es)
Inventor
Yonglian Zhang
Timothy John Hartingh
Tao Yu
John A Mccauley
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2023009445A publication Critical patent/MX2023009445A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MX2023009445A 2021-02-16 2022-02-14 Compuestos de heterociclos tetraciclicos utiles como inhibidores de la integrasa del vih. MX2023009445A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163149927P 2021-02-16 2021-02-16
PCT/US2022/016261 WO2022177840A1 (en) 2021-02-16 2022-02-14 Tetracyclic heterocycle compounds useful as hiv integrase inhibitors

Publications (1)

Publication Number Publication Date
MX2023009445A true MX2023009445A (es) 2023-08-25

Family

ID=80625127

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009445A MX2023009445A (es) 2021-02-16 2022-02-14 Compuestos de heterociclos tetraciclicos utiles como inhibidores de la integrasa del vih.

Country Status (11)

Country Link
US (1) US11958864B2 (https=)
EP (1) EP4294813B1 (https=)
JP (1) JP2024507788A (https=)
KR (1) KR20230147131A (https=)
CN (1) CN117083282A (https=)
AR (1) AR124868A1 (https=)
CA (1) CA3208396A1 (https=)
ES (1) ES3048138T3 (https=)
MX (1) MX2023009445A (https=)
TW (1) TW202246286A (https=)
WO (1) WO2022177840A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY201239A (en) 2019-03-22 2024-02-13 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
PE20221569A1 (es) 2020-02-24 2022-10-06 Gilead Sciences Inc Compuestos tetraciclicos para el tratamiento de infecciones por vih
ES3064867T3 (en) 2020-09-30 2026-04-29 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds for a use in the treatment of hiv
US11613546B2 (en) 2021-01-19 2023-03-28 Gilead Sciences, Inc. Substituted pyridotriazine compounds and uses thereof
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
EP4704976A1 (en) * 2023-04-28 2026-03-11 Merck Sharp & Dohme LLC Delivery devices for anti-hiv compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010011814A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
JP5551697B2 (ja) * 2008-07-25 2014-07-16 ビーブ・ヘルスケア・カンパニー 化合物
ES2448766T3 (es) * 2008-07-25 2014-03-17 Viiv Healthcare Company Profármacos de dolutegravir
DK2620436T3 (en) * 2010-09-24 2018-07-30 Shionogi & Co Substituted polycyclic carbamoylpyridone derivative prodrug
WO2017113288A1 (en) * 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
JOP20190130A1 (ar) * 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
EP3573984A4 (en) * 2017-01-26 2020-07-29 Merck Sharp & Dohme Corp. USEFUL SUBSTITUTE QUINOLIZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS

Also Published As

Publication number Publication date
AU2022223241A1 (en) 2023-08-24
EP4294813A1 (en) 2023-12-27
AR124868A1 (es) 2023-05-10
US20220259227A1 (en) 2022-08-18
KR20230147131A (ko) 2023-10-20
US11958864B2 (en) 2024-04-16
TW202246286A (zh) 2022-12-01
WO2022177840A1 (en) 2022-08-25
JP2024507788A (ja) 2024-02-21
ES3048138T3 (en) 2025-12-09
EP4294813B1 (en) 2025-09-10
CA3208396A1 (en) 2022-08-25
CN117083282A (zh) 2023-11-17

Similar Documents

Publication Publication Date Title
MX2023009445A (es) Compuestos de heterociclos tetraciclicos utiles como inhibidores de la integrasa del vih.
DOP2019000140A (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
DOP2023000168A (es) Compuestos antivirales que contienen nitrilo
UY37795A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
ECSP16016726A (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
UY39032A (es) Compuestos heterocíclicos como agentes antivirales
MX2020011317A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih.
UY38559A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
UY38614A (es) Derivados de benzodiazepinas como inhibidores del rsv
MX2019006449A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih).
MX2012006297A (es) Uso topico hidroxitirosol y derivados para la prevencion de la infeccion por vih.
UY39642A (es) Compuestos heterocíclicos antivirales
AR127470A1 (es) Inhibidores de lrrk2
CL2022002405A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
CO2025003090A2 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
MX2021009584A (es) Nuevos derivados de triterpeno como inhibidores del virus de la inmunodeficiencia humana (vih).
ECSP24007193A (es) Compuestos pirimidínicos para usar como inhibidores de map4k1
UY40025A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno, y composiciones far
MX2025014666A (es) Forma cristalina de sal sodica de derivados de piridona carbamoilica policiclica, su metodo de preparacion y aplicacion
UY39738A (es) Compuestos antivirales que contienen nitrilo
ECSP23075535A (es) Compuestos cíclicos y métodos de uso
CL2022001935A1 (es) Compuestos antivirales que contienen nitrilo
AR118379A1 (es) Derivados de benzodiazepinas como inhibidores del rsv